Project Details
Description
An observational study will be conducted using expanded molecular analysis of hundreds of single nucleotide polymorphisms (SNPs) in Colombian patients with refractory epilepsy, with respect to their response to phenytoin, in order to generate genomic profiles of susceptibility to adverse reactions (ARs) and drug resistance, reduce the impact on healthcare costs, and improve the quality of life of these patients.
This project is the result of collaboration between the CIGGUR, NEUROS, and URBIOMED research groups, which benefited from the call for proposals for the IX Meeting of Research Groups at the Universidad del Rosario 2024.
This project is the result of collaboration between the CIGGUR, NEUROS, and URBIOMED research groups, which benefited from the call for proposals for the IX Meeting of Research Groups at the Universidad del Rosario 2024.
Keywords
Pharmacogenomics, SNP microarrays, drug-resistant epilepsy, adverse drug reactions, precision medicine, phenytoin
| Short title | Pharmacogenomics epilepsy |
|---|---|
| Acronym | PE |
| Status | Active |
| Effective start/end date | 6/3/25 → 3/3/27 |
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Main Funding Source
- Incubator
Location
- Bogotá D.C.
Open Science
- Open research data
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.